Intravenous phenytoin: A retrospective analysis of Bayesian forecasting versus conventional dosing in patients

International Journal of Clinical Pharmacy

Volumn 35, Issue 5, 2013, Pages 790-797

  Tobler, Andrea ^a   Mühlebach, Stefan ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Bayesian forecasting; Conventional dosing; Hospital population; Medication management; Phenytoin; Therapeutic drug monitoring

Indexed keywords

PHENYTOIN;

ADOLESCENT; ADULT; AGE; ALGORITHM; ARTICLE; BAYES THEOREM; BODY WEIGHT; CHILD; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE; EMERGENCY CARE; EPILEPSY; FEMALE; FORECASTING; GROUPS BY AGE; HOSPITAL PATIENT; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEUROLOGY; NEUROSURGERY; OPEN STUDY; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SWITZERLAND; TEACHING HOSPITAL; VALIDATION STUDY;

AGE FACTORS; ANTICONVULSANTS; BAYES THEOREM; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; EPILEPSY; FEMALE; HOSPITALS, TEACHING; HUMANS; INDIVIDUALIZED MEDICINE; INFUSIONS, INTRAVENOUS; MAINTENANCE CHEMOTHERAPY; MALE; MODELS, BIOLOGICAL; OUTPATIENT CLINICS, HOSPITAL; PHENYTOIN; RECURRENCE; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; SEX CHARACTERISTICS; SWITZERLAND;

EID: 84886097160     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-013-9809-5     Document Type: Article

References (31)

1. Temkin NR, Dikmen SS, Wilensky AJ, Keihm J, Chabal S, Winn HR. A randomized, double-blind study of Phenytoin for the prevention of post-traumatic seizures. N Engl J Med. 1990;323:497-502.
2. Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia. 2001;42:515-24.
3. Schierhout G, Roberts I. Prophylactic antiepileptic agents after head injury: a systematic review. J Neurol Neurosurg Psychiatry. 1998;64:108-12.
4. Haltiner A, Newell DW, Temkin NR, Dikmen SS, Winn HR. Side effects and mortality associated with use of Phenytoin for early posttraumatic seizure prophylaxis. J Neurosurg. 1999;91:588-92.
5. Neels HM, Sierens AC, Naelaerts K, Scharpé SL, Hatfield GM, Lambert WE. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med. 2004;42:1228-55.
6. Brodie MR, Muir SE, Agnew E, MacPhee GJ, Volo G, Teasdale E, et al. Protein binding and CSF penetration of Phenytoin following acute oral dosing in man. Br J Clin Pharmacol. 1985;19:161-8.
7. Walker MC, Alavijeh MS, Shorvon SD, Patsalos PN. Microdialysis. Study of the Neuropharmacokinetics of Phenytoin in Rat Hippocampus and Frontal Cortex. Epilepsia. 1996;37:421-7.
8. Spruill WJ, Wade WE, Cobb HH, Akbari S. Three Michaelis-Menten pharmacokinetic dosing methods compared with physician dosing of Phenytoin in an outpatient neurology practice. Pharmacotherapy. 2001;21:1407-14.
9. Grasela TH, Sheiner LB, Rambeck B, Boenigk HE, Dunlop A, Mullen PW, et al. Steady-state pharmacokinetics of Phenytoin from routinely collected patient data. Clin Pharmacokinet. 1983;8:355-64.
10. Evens RP, Fraser DG, Ludden TM, Sutherland EW. Phenytoin toxicity and blood levels after a large oral dose. Am J Hosp Pharm. 1980;37:232-5.
11. ®. Arzneimittelkompendium der Schweiz. Basel: Documed AG; 2008. p. 3021-4.
12. ®. Arzneimittel-Kompendium der Schweiz. Basel: Documed AG; 2005. p. 997-1000.
13. Martinelli EF, Mühlebach SF. Rapid i.v. loading with phenytoin with subsequent dose adaptation using non-steady-state serum levels and a Bayesian forecasting computer program to predict maintenance doses. J Clin Pharm Ther. 2003;28:385-93.
14. Privitera MD, Homan RW, Ludden TM, Peck CC, Vasko MR. Clinical utility of Bayesian dosing program for phenytoin. Ther Drug Monit. 1989;11(3):285-94.
15. Crowley JJ, Koup JR, Cusack BJ, Ludden TM, Vestal RE. Evaluation of a proposed method for phenytoin maintenance dose prediction following an intravenous loading dose. Eur J Clin Pharmacol. 1987;32(2):141-8.
16. Yuen GJ, Taylor JW, Ludden TM, Murphy MJ. Predicting phenytoin dosages using Bayesian feedback: a comparison with other methods. Ther Drug Monit. 1983;5(4):437-41.
17. Garcia MJ, Gavira R, Santos Buelga D, Dominguez-Gil A. Predictive performance of two phenytoin pharmacokinetic dosing programs from nonsteady state data. Ther Drug Monit. 1994;16(4):380-7.
18. Gaulier JM, Boulieu R, Fischer C, Mauguiere F. Evaluation of a bayesian pharmacokinetic program for phenytoin concentration predictions in outpatient population. Eur J Drug Metab Pharmacokinet 1998;23(2):295-300.
19. Zaccara G, Messori A, Muscas GC, Albani F, Baruzzi A, Bianchi A, et al. Predictive performance of pharmacokinetic methods for phenytoin dosing: a multi-center evaluation in 282 patients with epilepsy. Epilepsy Res. 1989;3(3):253-61.
20. Godley PJ, Ludden TM, Clementi WA, Godley SE, Ramsey RR. Evaluation of a Bayesian regression-analysis computer program using non-steady-state phenytoin concentrations. Clin Pharm. 1987;6(8):634-9.
21. Martinelli EF. Therapeutisches Monitoring von Phenytoin im Krankenhaus: Untersuchung zur schnellen i.v.-Aufsättigung und Dosisvoraussage mittels Bayesian Forecasting, zur Laborbestimmung und zur Phänotypisierung der Metabolisierungsgeschwindigkeit. Bern: Schweizerische Nationalbibliothek; 1994.
22. Vozeh S, Uematsu T, Aarons L, Maitre P, Landolt H, Gratzl O. Intravenous phenytoin loading in patients after neurosurgery and in status epilepticus. A population pharmacokinetic study. Clin Pharmacokinet. 1988;14:122-8.
23. Swadron SP, Rudis MI, Azimian K, Beringer P, Fort D, Orlinsky MA. Comparison of Phenytoin-loading Techniques in the Emergency Department. Acad Emerg Med. 2004;11:244-52.
24. Hayes G, Kootsikas ME. Reassessing the lower end of the phenytoin therapeutic range: a review of the literature. Ann Pharmacother. 1993;27:1389-92.
25. Perucca E, Berlowitz D, Birnbaum A, Cloyd JC, Garrard J, Hanlon JT, et al. Pharmacological and clinical aspects of antiepileptic drug use in elderly. Epilepsy Res. 2006;68S:49-63.
26. Bach B, Hansen JM, Kampmann JP, Rasmussen SN, Skovsted L. Disposition of antipyrine and phenytoin correlated with age and liver volume in man. Clin Pharmacokinet. 1981;6:389-96.
27. Estruch J, Galdames D, Martinetti A, Saavedra I. Phenytoin pharmacokinetics in young and older adults. Rev Med Chil. 1992;120:1106-9.
28. Blain PG, Mucklow JC, Bacon CJ, Rawlins MD. Pharmacokinetics of phenytoin in children. Br J Clin Pharmacol. 1981;12(5):659-61.
29. Bauer LA, Blouin RA. Age and phenytoin kinetics in adult epileptics. Clin Pharmacol Ther. 1982;31:301-4.
30. Battino D, Croci D, Mamoli D, Messina S, Perucca E. Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data. Epilepsy Res. 2004;59:155-65.
31. Sketris IS, Langille Ingram EM, Lummis HL. Strategic opportunities for effective optimal prescribing and medication management. Can J Clin Pharmacol. 2009;16:e103-25.